– USA, CA – Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Scott Huennekens to its Board of Directors.
About R. Scott Huennekens
Scott Huennekens is a highly regarded medtech CEO, chairperson, entrepreneur, and investor, serving an impressive list of companies. Previously, he led Volcano Corp. (VOLC), a leader in minimally invasive therapy guidance in interventional cardiology, from start-up in 2002 to IPO to its sale to Philips in 2015. He was awarded E&Y’s entrepreneur of the year award in 2010 and was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference.
Scott Huennekens graduated magna cum laude with a BS in Business Administration from the University of Southern California and holds his MBA from the Harvard Business School.
About Endologix
Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas, and Santa Rosa, California.
For more: https://endologix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.